CN101224314B - 医用钛合金植入物表面抗生素缓释系统的构建方法 - Google Patents
医用钛合金植入物表面抗生素缓释系统的构建方法 Download PDFInfo
- Publication number
- CN101224314B CN101224314B CN2008100172962A CN200810017296A CN101224314B CN 101224314 B CN101224314 B CN 101224314B CN 2008100172962 A CN2008100172962 A CN 2008100172962A CN 200810017296 A CN200810017296 A CN 200810017296A CN 101224314 B CN101224314 B CN 101224314B
- Authority
- CN
- China
- Prior art keywords
- titanium alloy
- alloy implant
- implant surface
- medical titanium
- titanium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000007943 implant Substances 0.000 title claims abstract description 59
- 229910001069 Ti alloy Inorganic materials 0.000 title claims abstract description 45
- 230000003115 biocidal effect Effects 0.000 title claims description 21
- 238000013268 sustained release Methods 0.000 title claims description 15
- 239000012730 sustained-release form Substances 0.000 title claims description 15
- 238000000034 method Methods 0.000 title description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims abstract description 72
- 239000003814 drug Substances 0.000 claims abstract description 35
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 claims abstract description 33
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims abstract description 26
- 239000010936 titanium Substances 0.000 claims abstract description 25
- 229910052719 titanium Inorganic materials 0.000 claims abstract description 25
- 239000000203 mixture Substances 0.000 claims abstract description 19
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims abstract description 13
- 235000017557 sodium bicarbonate Nutrition 0.000 claims abstract description 13
- 239000004005 microsphere Substances 0.000 claims abstract description 12
- 239000000654 additive Substances 0.000 claims abstract description 10
- 230000000996 additive effect Effects 0.000 claims abstract description 10
- 229940079593 drug Drugs 0.000 claims abstract description 10
- 238000005245 sintering Methods 0.000 claims abstract description 10
- 239000000126 substance Substances 0.000 claims abstract description 9
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 8
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 8
- 238000010276 construction Methods 0.000 claims abstract description 5
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 claims description 25
- 208000015181 infectious disease Diseases 0.000 claims description 16
- 239000010410 layer Substances 0.000 claims description 15
- 239000000463 material Substances 0.000 claims description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 10
- 210000000988 bone and bone Anatomy 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 150000001718 carbodiimides Chemical class 0.000 claims description 7
- 239000003431 cross linking reagent Substances 0.000 claims description 7
- 239000000243 solution Substances 0.000 claims description 7
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 239000011247 coating layer Substances 0.000 claims description 6
- 230000008878 coupling Effects 0.000 claims description 6
- 238000010168 coupling process Methods 0.000 claims description 6
- 238000005859 coupling reaction Methods 0.000 claims description 6
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 claims description 6
- 229960002163 hydrogen peroxide Drugs 0.000 claims description 6
- 239000011259 mixed solution Substances 0.000 claims description 6
- 238000012986 modification Methods 0.000 claims description 6
- 230000004048 modification Effects 0.000 claims description 6
- 238000004659 sterilization and disinfection Methods 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 238000004506 ultrasonic cleaning Methods 0.000 claims description 6
- 238000001291 vacuum drying Methods 0.000 claims description 6
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims description 5
- 229930182566 Gentamicin Natural products 0.000 claims description 5
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 5
- ZWIBGKZDAWNIFC-UHFFFAOYSA-N disuccinimidyl suberate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCCC(=O)ON1C(=O)CCC1=O ZWIBGKZDAWNIFC-UHFFFAOYSA-N 0.000 claims description 5
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 claims description 5
- 229960001225 rifampicin Drugs 0.000 claims description 5
- 238000004140 cleaning Methods 0.000 claims description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 3
- 235000021355 Stearic acid Nutrition 0.000 claims description 3
- 235000013877 carbamide Nutrition 0.000 claims description 3
- 239000004202 carbamide Substances 0.000 claims description 3
- 229920000609 methyl cellulose Polymers 0.000 claims description 3
- 239000001923 methylcellulose Substances 0.000 claims description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 3
- 239000008117 stearic acid Substances 0.000 claims description 3
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 claims description 3
- 229960002317 succinimide Drugs 0.000 claims description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims description 2
- 150000003672 ureas Chemical group 0.000 claims 1
- 229910052751 metal Inorganic materials 0.000 abstract description 8
- 239000002184 metal Substances 0.000 abstract description 8
- 108010010803 Gelatin Proteins 0.000 abstract description 2
- 238000010521 absorption reaction Methods 0.000 abstract description 2
- 229920000159 gelatin Polymers 0.000 abstract description 2
- 239000008273 gelatin Substances 0.000 abstract description 2
- 235000019322 gelatine Nutrition 0.000 abstract description 2
- 235000011852 gelatine desserts Nutrition 0.000 abstract description 2
- 239000003242 anti bacterial agent Substances 0.000 abstract 3
- 229940088710 antibiotic agent Drugs 0.000 abstract 3
- 239000011324 bead Substances 0.000 abstract 3
- 239000004971 Cross linker Substances 0.000 abstract 2
- 206010031252 Osteomyelitis Diseases 0.000 abstract 1
- VWUGXQPRODYJFD-UHFFFAOYSA-N di(imidazol-1-yl)methanone propan-2-one Chemical compound CC(=O)C.C(=O)(N1C=NC=C1)N1C=NC=C1 VWUGXQPRODYJFD-UHFFFAOYSA-N 0.000 abstract 1
- 238000002604 ultrasonography Methods 0.000 abstract 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 20
- 238000000576 coating method Methods 0.000 description 12
- 239000011248 coating agent Substances 0.000 description 10
- 230000000694 effects Effects 0.000 description 8
- 239000007769 metal material Substances 0.000 description 7
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 4
- 230000002924 anti-infective effect Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 229910052709 silver Inorganic materials 0.000 description 3
- 239000004332 silver Substances 0.000 description 3
- TVZRAEYQIKYCPH-UHFFFAOYSA-N 3-(trimethylsilyl)propane-1-sulfonic acid Chemical compound C[Si](C)(C)CCCS(O)(=O)=O TVZRAEYQIKYCPH-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 206010067268 Post procedural infection Diseases 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- LNQHREYHFRFJAU-UHFFFAOYSA-N bis(2,5-dioxopyrrolidin-1-yl) pentanedioate Chemical compound O=C1CCC(=O)N1OC(=O)CCCC(=O)ON1C(=O)CCC1=O LNQHREYHFRFJAU-UHFFFAOYSA-N 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 229920001432 poly(L-lactide) Polymers 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- IECPWNUMDGFDKC-UHFFFAOYSA-N Fusicsaeure Natural products C12C(O)CC3C(=C(CCC=C(C)C)C(O)=O)C(OC(C)=O)CC3(C)C1(C)CCC1C2(C)CCC(O)C1C IECPWNUMDGFDKC-UHFFFAOYSA-N 0.000 description 1
- 241000906034 Orthops Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical compound O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 1
- 229960004675 fusidic acid Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
Images
Landscapes
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008100172962A CN101224314B (zh) | 2008-01-15 | 2008-01-15 | 医用钛合金植入物表面抗生素缓释系统的构建方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008100172962A CN101224314B (zh) | 2008-01-15 | 2008-01-15 | 医用钛合金植入物表面抗生素缓释系统的构建方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101224314A CN101224314A (zh) | 2008-07-23 |
CN101224314B true CN101224314B (zh) | 2011-04-20 |
Family
ID=39856659
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2008100172962A Expired - Fee Related CN101224314B (zh) | 2008-01-15 | 2008-01-15 | 医用钛合金植入物表面抗生素缓释系统的构建方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101224314B (zh) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101791439B (zh) * | 2010-04-08 | 2013-01-09 | 中国人民解放军第四军医大学 | 医用钛合金植入物表面生长因子缓释系统的构建方法 |
CN102293693B (zh) * | 2011-06-01 | 2013-06-26 | 中国人民解放军第四军医大学 | 一种具有生物活性多孔钛合金人颈椎间融合器及其制备方法 |
CN103705294B (zh) * | 2012-09-28 | 2016-03-02 | 上海微创骨科医疗科技有限公司 | 多功能复合药物涂层缓释系统及其制备方法 |
CN103143066A (zh) * | 2013-02-01 | 2013-06-12 | 北京市理化分析测试中心 | 一种新的用于医疗器械载药的组合物 |
CN104274862B (zh) * | 2014-09-17 | 2016-08-24 | 上海施必康医疗器械有限公司 | 一种颅颌面修复钛网表面活性药物缓释涂层的制备方法 |
CN106540320A (zh) * | 2016-12-13 | 2017-03-29 | 天津高卓科技有限公司 | 一种节能环保型植入医疗器械上药物涂层的涂覆方法 |
CN113633437A (zh) * | 2021-08-09 | 2021-11-12 | 北京科技大学 | 一种钛合金多孔骨植入体及制备方法 |
CN116271210A (zh) * | 2023-04-21 | 2023-06-23 | 国纳之星(上海)纳米科技发展有限公司 | 一种仿生骨修复涂层改性的钛合金及其制备方法 |
-
2008
- 2008-01-15 CN CN2008100172962A patent/CN101224314B/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN101224314A (zh) | 2008-07-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101224314B (zh) | 医用钛合金植入物表面抗生素缓释系统的构建方法 | |
Mondal et al. | 3D hydroxyapatite scaffold for bone regeneration and local drug delivery applications | |
Zhu et al. | 3D-printed hierarchical scaffold for localized isoniazid/rifampin drug delivery and osteoarticular tuberculosis therapy | |
Zhu et al. | A mesoporous silica nanoparticulate/β-TCP/BG composite drug delivery system for osteoarticular tuberculosis therapy | |
ES2730410T3 (es) | Material para el tratamiento de insuficiencia cardíaca avanzada como dispositivo de regeneración miocárdica/cardiovascular | |
Le Ray et al. | Vancomycin encapsulation in biodegradable poly (ε-caprolactone) microparticles for bone implantation. Influence of the formulation process on size, drug loading, in vitro release and cytocompatibility | |
ES2900336T3 (es) | Composiciones basadas en tejido y métodos de uso de las mismas | |
US20080311172A1 (en) | Programmed-release, nanostructured biological construct | |
US20160008469A9 (en) | Method for preparing biomedical metal alloy material with multi-drug delivery system | |
US20060093670A1 (en) | Sustained-release composition process for producing the same and preparation thereof | |
Soundrapandian et al. | Organic–inorganic composites for bone drug delivery | |
EP1207915A1 (en) | Novel multilayered material bearing a biologically active agent and the preparation thereof | |
Sidney et al. | Investigation of localized delivery of diclofenac sodium from poly (D, L-lactic acid-co-glycolic acid)/poly (ethylene glycol) scaffolds using an in vitro osteoblast inflammation model | |
JP5758904B2 (ja) | ニトライトの医薬製剤及びそれらの使用 | |
WO2014048208A1 (zh) | 多功能复合药物涂层缓释系统及其制备方法 | |
WO2022012339A1 (zh) | 一种构建骨形态发生蛋白缓释系统的方法 | |
CN103705988B (zh) | 一种具有多功能涂层的髓内钉及其制备方法 | |
Jeong et al. | Augmented re-endothelialization and anti-inflammation of coronary drug-eluting stent by abluminal coating with magnesium hydroxide | |
Tabernero et al. | Supercritical carbon dioxide and biomedicine: Opening the doors towards biocompatibility | |
Xi et al. | BMP2‐mimicking peptide modified with E7 coupling to calcined bovine bone enhanced bone regeneration associating with activation of the Runx2/SP7 signaling axis | |
CN110087705A (zh) | 多相凝胶 | |
Wang et al. | Implantable and biodegradable macroporous iron oxide frameworks for efficient regeneration and repair of infracted heart | |
Wang et al. | 3D printing of multi-functional artificial conduits against acute thrombosis and clinical infection | |
Lasserre et al. | Ceramic drug-delivery devices | |
Zhou et al. | Novel coatings for the continuous repair of human bone defects |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: THE 4TH MILITARY SURGEON UNIV. P. L. A. Free format text: FORMER OWNER: GUO ZHENG Effective date: 20140808 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 710049 XI'AN, SHAANXI PROVINCE TO: 710032 XI'AN, SHAANXI PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20140808 Address after: 710032 Changle West Road, Shaanxi, China, No. 169, No. Patentee after: The Fourth Military Medical University of the Chinese People's Liberation Army Address before: Five Department of bone, Xijing Hospital,, 15 West Changle Road, Xi'an, Shaanxi, 710049 Patentee before: Guo Zheng |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110420 Termination date: 20200115 |